Syndeio Biosciences
Syndeio Biosciences raises $90M Series at $450M valuation
Quick Facts
Syndeio Biosciences: Series Funding Round
Syndeio Biosciences has successfully raised $90M in Series funding, reaching a valuation of $450M.
Company Overview
Developer of precision neurotherapeutics for CNS diseases
Funding Details
The Series round was led by Eli Lilly and Company, with participation from ARCH Venture Partners.
Company Information
- Headquarters: Indianapolis, IN
- Founded: 2022
- Employees: 60+
- Category: Biotech
Investment
Syndeio Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Eli Lilly and Company: Verified investor in Series
- ARCH Venture Partners: Verified investor in Series
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...